Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 4/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.40 |
| ▸ | NPY1R | P25929 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | QPCT | Q16769 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427820 | 0.93 | SYK (0.38) | NMT1HRH4NPY1RACHEQPCT | |
| SCHEMBL16011707 | 0.79 | HRH4 (0.51) | HRH4HRH3GRIN2B | |
| SCHEMBL426645 | 0.76 | HRH4 (0.44) | NMT1HRH4NPY1RACHEROCK1 | |
| SCHEMBL21715689 | 0.73 | TDP1 (0.49) | HRH3 | |
| SCHEMBL19004848 | 0.71 | ACACB (0.40) | RXRAGRIN1GRIN2B | |
| SCHEMBL426711 | 0.71 | HRH4 (0.42) | NMT1HRH4NPY1RACHEQPCT | |
| SCHEMBL18081852 | 0.71 | MAPK8 (0.45) | RXRAGRIN1GRIN2B | |
| SCHEMBL24798573 | 0.70 | RXRA (0.40) | RXRAGRIN1GRIN2B | |
| SCHEMBL14345363 | 0.69 | MAPK8 (0.43) | RXRAGRIN1GRIN2B | |
| SCHEMBL426634 | 0.69 | CTSL (0.41) | NMT1HRH4ACHEHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | NMT1 1456/4885HRH4 481/4885NPY1R 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.